Download: PDF RTF XML Booklet: Review (0) Retrieve Add item
European Joint Action on Vaccination [EU-JAV] [801495] - Joint Actions
Coordination of the project by lead INSERM

Start month:1 - End month: 36

Task 1.1 : Strategic steering and support to governance
Leader: INSERM / Contributors: Governance bodies ; Start date: M1 End date: M36
Task description: The following governance structure will ensure...
Task 1.1 : Strategic steering and support to governance
Leader: INSERM / Contributors: Governance bodies ; Start date: M1 End date: M36
Task description: The following governance structure will ensure the relevance of the EU-JAV activities in line with the workplan and national strategies. This task involves setting up and managing the relevant steering and management bodies introduced in section 9 and fully described in appendix.
General Assembly: Board with decision power related to the Joint Action Vaccination, composed of one representative per associated partner
• Executive Board: Board in charge of executive decisions and overseeing daily activities, composed of coordination and WP leaders
• Member States Committee: Board in charge of strategic orientations and composed of one representative (competent authority) from each Member State. The members will be nominated at the start of the project.
• Stakeholders forum: composed of stakeholders including DG SANTE, ECDC, WHO-Europe, EMA, OECD, health professionals, patients and civil society as well as industry representatives, and others as needed (see section 9 for details).
• A vaccine network will gather both the Member State Committee and the Stakeholders forum. More details can be found in WP4, task 4.1.

Task 1.2: Contractual and financial management
Leader: INSERM / Contributors: WP Leaders ; Start date: M1 End date: M36
Task description: The Joint Action Secretariat (JAS) will coordinate this task and will be responsible for the day-to-day management. It is composed of the project coordinator (INSERM) assisted by resources including a project manager based at INSERM. The JAS will be in charge of:
• Preparing the Consortium Agreement to be signed by all associated partners at the start of the project;
• Evaluating and monitoring the project costs in order to oversee and check the overall costs incurred per Work package and per associated partners (beneficiaries);
• Managing and distributing EC payments;
• Assisting individual project partners on specific administrative and financial issues
The JAS will meet monthly and will hold trimester teleconferences with the Executive Board to share updates on progress of the WPs.
Two annual meetings will be organised after the kick‐off at M12 and M24 and a final meeting at M36, in order to allow all management boards and partners to meet. As much as possible, these annual meetings will be organized back to back to the European Immunization Week (April). A private space intended to allow EU-JAV partners to share documents will be created in the EU-JAV website (in accordance with WP2 tools).

Task 1.3 : Periodic reporting
Leader: INSERM / Contributors: Executive Board (technical), All partners (financial reporting) ; Start date: M1 End date: M36
Task description: This task will:
• Monitor the progress of the project in terms of deliverables, milestones, etc., using dedicated project management tools;
• Identify and monitor risks and propose appropriate mitigation measures to the General Assembly
• Prepare one interim periodic and final reporting to ensure timely and efficient submission to the EC
• The project coordinator will act as the official representative towards the Chafea and DG SANTE. The project coordinator will provide them with two interim reports and a final report, assisted by the Project Manager at Inserm Bordeaux and with the support of a project manager at Inserm Transfert who will have an advisory role.

Task 1.4 : Communication
Leader : INSERM / Contributors: All partners ; Start date: M1 End date: M36
Task description: The following activities will be carried out:
• Use the project website to be set up in WP2. It will act as a platform to share all internal project documents;
• Support WP collaboration and interactions through regular web/audio conferences on demand and initiated by WP leaders;
• Act as liaison with coordinators or contact points of other ongoing or recen
Dissemination of the EU-JAV results by lead HCDCP

Start month:1 - End month: 36

WP Methodology
Website platform created for internal and public information sharing. Regular quality checking of the website.
Contact person designated by each partner. Communication between the WP2 l...
WP Methodology
Website platform created for internal and public information sharing. Regular quality checking of the website.
Contact person designated by each partner. Communication between the WP2 leader and each WP contact person via EU-JAV website, email and teleconference.
English as primary language for main dissemination tools (website, leaflet, layman report...) and materials. Each partner free to translate the material in its own language. Systematic review for the mapping activities.

Task descriptions
Task 2.1 : Stakeholder mapping
Leader HCDCP Contributors: Inserm, MoCA, ISS, CDPC, SAM, CPSU, RIVM, FHI, NIPH, IPHS, SK MoH, NIJZ, FMS, FOHM ; Start date: M01 End date: M04
Task description: This task aims at mapping the stakeholders involved in vaccination in all MS/partners involved in the JA including existing networks and EU-funded or international projects. This task will take place at the beginning of the project. The objective is to identify through systematic review all categories of the population who could directly benefit from the project (professionals, population groups, patients, citizens), who could be the best advocates (policy makers, Member States governments, health managers, private sector) or who could develop resistance (anti-vaccination movement, health professionals). As a starting point, each country has been asked to provide a detailed list of key stakeholders before the beginning of the project at both the national and international levels (See Section 14 Collaborating Stakeholders). Further work will be done on 1) the potential involvement of stakeholders 2) the key messages to share with them throughout the project and 3) information to be provided by the stakeholders.


Task 2.2 : Dissemination Plan
Leader HCDCP Contributors: Inserm, MoCA, ISS, CDPC, SAM, CPSU, RIVM, FHI, NIPH, IPHS, SK MoH, NIJZ, FMS, FOHM & all partners Start date: M01 End date: M04
Task description: The Dissemination Plan (DP) will be developed by a team of communication and health professionals at KEELPNO in collaboration with the coordinator and WP leaders. The DP will use results of task 2.1 to implement clear distribution of work needed to disseminate relevant information to stakeholders and the public. The DP will also include the development of the project logo and brand materials of the project (e.g. website, report, ppt templates, press release templates, communication kit, etc.).

2.2.1. An EU-JAV strategic Dissemination Plan
Leader: HCDCP
Start date: M01 End date: M04
Contributors: INSERM, NIPH, ISS, NIJZ, IPHS, FMS, CDPC, all partners
The leading partner will produce a “Dissemination Strategy” including:
1. Goals of the Dissemination
2. Information and Publicity requirements
3. Description of EU-JAV Target Groups
4. Description of EU-JAV Key Messages
5. Communication means and tools
6. National and European and Dissemination Plans
7. Dissemination guidelines
8. Monitoring of Dissemination activities.
The deliverable EU-JAV strategic Dissemination Plan will be prepared by M03 and it will be circulated within the EU-JAV contributors; local national dissemination plans will be prepared and adapted in English by each partner and will be included in this document, to be finished and submitted by M06.
2.2.2 EU-JAV Project Logo creation
Leader: HCDCP
Start date: M01 End date: M03
Contributors: INSERM, NIPH
The EU-JAV vision and mission will be determined and the project logo will be created. Project’s leaflets will be designed at the beginning, by M03, and will be promoted and exchanged with other EC projects, health agencies, etc.
2.2.3 EU-JAV Press Communication Kit
Leader: HCDCP
Start date: M01 End date: M03
Contributors: INSERM, NIPH
Journalists will be targeted by a Press Communication Kit, available in English. Communicators, journalists and policy makers will receive regular press releases during the whole project life. It will establish a coordinated presence on social media: Facebook P
Evaluation by lead FoHM

Start month:1 - End month: 36

WP Methodology
Set of indicators evaluating process, outcome/output, impact
Logical framework approach
Quantitative (questionnaires, surveys) and qualitative (in-depth interviews) evaluation methods.
...
WP Methodology
Set of indicators evaluating process, outcome/output, impact
Logical framework approach
Quantitative (questionnaires, surveys) and qualitative (in-depth interviews) evaluation methods.
Baseline and follow-up assessments to measure progress.

Task 3.1 : Elaboration of the evaluation plan
Leader FOHM Contributors: All partners ; Start date: M01 End date: M06
Task description: The task will finalise the evaluation plan based on the plans available at M1 for all the other WPs. The evaluation plan will examine both the process and effect (outcome and impact) of the vertical and horizontal WPs of the project through a systematic appraisal in terms of results (if the objectives were met) and in terms of quality (whether the outcomes meet the needs of the target groups).
Evaluation will pay specific attention to the sustainability of activities, e.g. inclusion of activities at the national levels and if they are firmly embedding in organizations or policies. The evaluation will also include shared lessons learned for the future. Baseline assessments will be prioritized aiming for M02-M04.

Major steps in the evaluation plan include i) a round table meeting at the beginning of the EU-JAV with all WP leaders for coordination and agreement on indicators and targets with the aim of applying a logical framework approach; ii) development of the evaluation design and methods; including the tools for evaluation; iii) formulate questionnaires and baseline assessments based on existing data and expectations of stakeholders. This initial assessment will include a mapping of already existing structures to avoid duplications and maximise incorporation of existing work and knowledge. If the information is not available elsewhere a questionnaire to partners and stakeholders on national vaccination programmes and vaccination coverage will be included in the baseline assessment in cooperation with WP8 (task 8.1 of the proposal- analysis on best practices and lessons learnt on vaccine coverage). Questions on social, cultural and behavioural aspects will be included in the assessment.
iv

The evaluation logical frameworks with objectives, indicators and sources of verification will be designed for all WPs. Each WP will have its own evaluation framework with activities, specific objectives and aims/results. It will also describe the specific data that will be collected, the means and methods that will be used for data collection, analysing procedures and reporting. The indicators should preferably abide by the SMART criteria. The evaluation frameworks will serve as a guide throughout the project. If necessary, due to circumstances, the frameworks can be adapted and further fine-tuned during the project. A preliminary list on examples of process and impact indicators with targets, as suggested by WP leads, is included in the proposal (Section 2.2 Specific objectives of the proposal).

NIPH will be involved in developing check lists, in cooperation with WP1, for process evaluation and monitoring of the WPs to be used by the individual WP leaders. NIPH will participate in the development and follow up of the baseline assessment tool/questionnaire targeting programme managers. NIPH will also contribute to the report on the baseline assessment and the follow-up assessment to be included in the midterm and final evaluation report.



Task 3.2 : Systematic assessment, monitoring and evaluation of EU-JAV
Leader FOHM / Contributors: Inserm, MoCA, HCDCP, ISS, CDPC, SAM, CPSU, RIVM, FHI, NIPH, IPHS, SK MoH, NIJZ, FMS, FOHM ; Start date: M01 End date: M36
Task description:
The evaluation process is ongoing throughout the project, assessing the implementation of planned actions so that timely interventions and necessary corrections can be made both regarding factors related to process as well as effect, thus improving the possibility to achieve the expected outcomes and impacts of the project. Coordination with the monitoring processes of WP1 is e
Integration in national policies and sustainability by lead INSERM

Start month:1 - End month: 36

WP Methodology
The plan to build on deliverables and activities developed within the WPs 5 to 8.
Integrative exercise of a review of common issues, priorities identified by MS and the outcomes of the...
WP Methodology
The plan to build on deliverables and activities developed within the WPs 5 to 8.
Integrative exercise of a review of common issues, priorities identified by MS and the outcomes of the whole EU-JAV. Pilot actions will explore the feasibility of joint public health actions in targeted areas.
A vaccine network to coordinate the progress of the sustainable development plan. In parallel, 3 pilot actions to explore the feasibility of joint and concrete Public Health actions.
Electronic survey targeting health care workers (needs for training, mapping unmet needs). Liaisons with relevant projects, specifically VENICE, or other Joint Actions, particularly the JA on antimicrobial resistance (EU-JAMRAI) and the JA in preparation on Health Technology Assessment, where appropriate, through the coordination team (WP1).

Task descriptions

Task 4.1: Establish a vaccine network
Leader: INSERM (MoH) / Contributors: all partners
Collaborating partners: ECDC, WHO Euro, EMA, EFPIA
Involvement of DG SANTE
Start date: M1 End date: M36
Task description: The vaccine network will play a pivotal role in ensuring the sustainability of actions at the EU level after the project ends. The intention is for the vaccine network to become an inclusive platform for the preparation of key decision-making. Throughout the project, the vaccine network will ensure that ways to leverage sustainability beyond the project are identified. For example, EU-JAV will ensure that both the vaccination priorities and target populations flagged by all countries as well as the tools needed to improve the context will be taken into consideration.

The vaccine network will include 2 governance bodies of the EU-JAV: the Member State Committee and the stakeholder forum (see Section 9 on EU-JAV governance structure). The MS representatives from the Member State Committee will have a decisive role with regard to strategic orientations of the vaccine network, particularly to sustain actions.
The Ministry of Health of all MSs will be invited to nominate a representative to establish the Member State Committee. Representatives of European institutions, namely, DG SANTE, EMA, ECDC, OECD, and organizations like WHO EURO will also be invited to participate in the Stakeholder Forum, as well as representatives from the civil society through representative bodies or community key opinion leaders, healthcare professionals, NGOs, industry (like EFPIA), scientific community and other stakeholders involved in vaccines. The purpose of the vaccine network will be to review the “national integration & sustainability” as it develops, as well as comment and input the pilot actions. Its main task under WP4 is to ensure sustainability and full coherence and convergence towards an EU action plan. The meetings of the vaccine network will be convened by the coordinator of the JA, in close cooperation with WP4 leader. Terms of reference for the vaccine network will be developed, including composition, mission, role, rules for information sharing and for governance of the information (D4.1).
Task 4.2: Develop an “integration into national policies & sustainability” plan
Leader: INSERM (MoH)/ Contributors: NIPH, THL
Start date: M3 End date: M36
Task description: Common and feasible public health actions are crucial to implement so as to tackle the main current vaccination-related issues and foster cross country cooperation. The plan will hence strive towards a converging vaccine agenda for the most commonly used vaccines at EU level, with a priority for the population of children and adolescents. The social and cultural background will be accounted for in the implementation guidelines. Outcomes from WP6 regarding the potential of the Joint Procurement Agreement will be carefully considered.
The plan (D4.2) will be drafted and submitted for comments to the vaccine network (task 4.1). A yearly review will be organized with email consultations prior to technical meetings.
The fi
Immunization Information systems to strengthen surveillance and increase vaccination coverage by lead SSI

Start month:1 - End month: 36

Co-WP leader: CIPH (HR)

The assessment of interoperability and a vaccine reminder system will be conducted through a common survey of IIS holders in the EU area. The survey will be designed in collab...
Co-WP leader: CIPH (HR)

The assessment of interoperability and a vaccine reminder system will be conducted through a common survey of IIS holders in the EU area. The survey will be designed in collaboration with contributing partners of the JA, and external experts of relevant stakeholders (ECDC), who will also participate in technical meetings to design the survey, the functional specification of the pilot platform, and preliminary analysis of survey results. The development of the pilot platform will be subcontracted, but the implementation and governance will be the responsibility of the WP5 leaders and contributors. The feasibility study under task 5.4 will consider outputs and preliminary reports from the JA activities, as well as external sources in its implementation.
Link with existing projects, including ADVANCE (methods for vaccine coverage estimation), and electronic vaccine records (e.g. “mesvaccins.net”)
Link with the forthcoming Joint Action on health information to ensure consistency between work done in this WP and the overall issue of health information system improvement.
Technical meetings will be organized to gather all partners and relevant expertise at M3, M9, M19 and M27. The meetings will be common for all and not divided on the specific tasks.

Task 5.1: Assess the Interoperability/harmonisation of European IIS
Leader: CIPH / Contributors: SSI, INSERM, VAZG, MoCA, MoH HPDPD, THL, HCDCP, ISS, CDPC, SAM, RIVM, FHI, NIJZ, FMS, FOHM
Collaborating partners: ECDC, PHE
Start date: M1 End date: M24
Task description:
• Conduct an assessment on the data quality, data collection processes, and interoperability of IIS’s in Europe using survey and semi-structured interviews with relevant registry and database owners;
• Assess compliance of existing IIS’s to the New European Interoperability Framework;
• Assess information on current methodology used to estimate MMR coverage and review other existing methodologies (to be used in the construction of an algorithm as part of task 5.2);
• Collect information from key stakeholders to identify challenges and needs related to information-sharing with regards to IIS implementation and prerequisites for implementation for a common platform, taking into account structural (e.g. ownership of data) and legal (e.g. data confidentiality, privacy protection) specifications;
• Develop a core minimum data model and specify core functionalities for use within a common platform for cross-border vaccine coverage assessment;
• Produce functional specifications for the pilot platform to be produced in Task 5.2.;
• Produce a report regarding current state of data collection and interoperability of IIS and vaccine data in the EU area.

Task 5.2. Pilot platform for cross-border vaccine coverage assessment
Leader: SSI / Contributors: CIPH, FOHM, THL, SK MoH, CDPC, RIVM, VAZG
Collaborating partners: ECDC, PHE
Start date: M18 End date: M30
Task description: European vaccination coverage data have been collected by WHO and within projects such as VENICE III. We will attempt to provide cross-Europe MMR vaccination coverage using a standardized approach with the following steps:
• Develop a protocol for harmonized estimations of vaccination coverage of MMR1 and MMR2 including definition of variables to be included in the core data model based on deliverables from Task 5.1.; the aim is for the protocol to be adopted by at least 2-3 countries with common borders.
• Distribute an open-source computer algorithm that can be shared and run by regions, countries with IIS or other similar data source, completed by data on doses of Measles Containing Vaccines (MVC);
• Deploy a common pilot platform where vaccine coverage estimations for cross-border vaccine coverage assessments can be shared publicly;
• Recruit key stakeholders to contribute content and participate in the pilot platform;
• Implement additional functionalities based on needs and gaps identified in t
Vaccine supply and preparedness by lead ISS

Start month:1 - End month: 36

Co-WP leader: FHI

Build on existing experience of MSs, collected through surveys and relevant documents (grey literature) gathered from key stakeholders identified at National level both within publi...
Co-WP leader: FHI

Build on existing experience of MSs, collected through surveys and relevant documents (grey literature) gathered from key stakeholders identified at National level both within public health institutions (MoHs, PHIs, regulatory agencies, ECDC, WHO, EU and MS Joint Procurement Agreements and NITAGs) and industry (Vaccines Europe). The potential of the Joint Procurement Agreement mechanism will be carefully analysed. Open dialogue to be initiated with industry on supply.
A concept for an EU data warehouse will be developed, in preparation for a full database. Legal constraints and ethical challenges to the concept will be discussed. The affordability issue will be addressed and recommendations on how this can be managed beyond the project will be put forward.
Links with existing projects, including VENICE (information-sharing on national vaccination programmes, ECDC).

Task descriptions
Task 6.1: Forecasting of vaccine needs and demand
Leader ISS / Contributors INSERM, MoCA, THL, FMS, FHI, RIVM, HCDCP, CDPC, SSI, SAM, CPSU, NIJZ
Collaborating partners: ECDC, WHO, EMA, Vaccine Europe
Start date: M1 End date: M36
Task description: This task will map vaccine demand at the European level to ensure adequate availability of high quality vaccines and estimate financial needs to conduct immunisation programmes. The mapping will be based on data gathered from the national regulatory agencies, public health institutes, ministries of health (MoH) and product manufacturers that can provide information on past vaccine supply, vaccination programmes and projections and can evaluate future needs. This data will be collected from the MSs through the collaboration with MS’s country procurement and supply units and other relevant stakeholders as foreseen in WP4 (task 4.3). Rules established in WP4 (task 4.1) for information-sharing and governance of the information will apply also for this WP.
6.1.1 Review previous experiences on vaccine shortage and evaluate the response at national and at EU level as well as elaborate realistic procedures to share relevant information from industry about potential vaccine shortages.
6.1.2 Capitalise on existing initiatives, elaborate procedures and methods to estimate needs and procurement of vaccines in the different countries in the short and long-term (5-10 years) and share information among MSs. We will define the type of products and different actions to be undertaken depending on the level of risk (linked to Task 4.2).
6.1.3 Analyse and evaluate the local financing mechanisms useful to identify original solutions to ensure sustainable purchase and stock of vaccines to the EU countries.

Task 6.2: Mechanisms of management of supply and stocks
Leader: FHI / Contributors INSERM, MoCA, THL, FMS, ISS, RIVM, HCDCP, CDPC, SSI, SAM, CPSU, NIJZ
Collaborating partners: ECDC, WHO, EMA, Vaccine Europe
Start date: M1 End date: M36
Task description: Based on existing experiences and platforms (e.g. EPIS) we will explore the feasibility and a concept to build a European system to prevent shortages. The final outcome of this Task will be to improve exchange of vaccine stocks between countries in cooperation with vaccine industry. A midterm meeting with the WP6 participants and relevant stakeholders will take place, preferably in connection to the General Assembly at M12 to obtain expert feedback and advice to build the concept.
6.2.1 Develop a plan with industry and other stakeholders to anticipate changes in vaccine recommendations and, more accurately, gain critical information to ensure preparedness as well as improving the forecast of vaccine demand of specific priority vaccines in the routine immunization schedule and manufacturing planning (in cooperation with Task 6.1). In doing so, this would reduce risks for both the purchaser and manufacturer and decrease the risk of vaccine shortages and stock-outs. The plan will recommend mechanisms for defining the anticipated needs (i.e. geographical
Vaccine research and development priority-setting framework by lead INSERM

Start month:1 - End month: 36

Co-WP leader: FHI

Consultations, systematic review, consensus methods, quantitative and qualitative surveys of experts, institutions and companies in charge of gathering and setting priorities for va...
Co-WP leader: FHI

Consultations, systematic review, consensus methods, quantitative and qualitative surveys of experts, institutions and companies in charge of gathering and setting priorities for vaccine research, mapping of disciplines needed and their scientific societies, sociological, economic and public methods (“payback”) to build indicators and processes for setting priorities.
Mapping and critical assessment of existing and possible funding mechanisms for identified priorities along the value chain
Links with major tools used for R&D vaccine research and development, including WHO R&D Blueprint, CEPI (Coalition for Epidemic Preparedness Innovations), UK Vaccine Network, EC/IMI, BARDA, GHIT (Global Health Innovative Technology Fund), DG Research, NIH/NIAID
Links with other EU-funded initiatives related to vaccine R&D, including the Joint Action on AMR and Healthcare Associated Infection
Links with industry

Task descriptions
Task 7.1. Priorities for vaccine research and development.
Leader INSERM / Contributors: THL, FMS, ISS, RIVM, HCDCP, FOHM, FHI, MoCA
Collaboration needed with MS research bodies, MoH, NITAG, DG research, DG SANTE, ECDC, EMA, EFPIA, WHO, WHO EURO, NGOs, civil society, parents’ associations, initiatives to develop new vaccines, etc.
Start date: M2 End date: M24
Objective: Establish a process involving all relevant stakeholders to develop a concept and prototype research priority setting framework to identify critical needs and priorities in terms of vaccine and vaccination research (over the whole value chain from basic, clinical and epidemiological to social and societal aspects of hesitancy) to increase vaccination coverage in EU MS.

Sub-Task 7.1.1: Identify a subset of 3-6 different vaccines for different stages of life to be used as pilots
Start date: M2 End date: M6
Task description: As vaccination issues are quite different depending on age, three pilots categories will be used to develop this task in an exhaustive way: this task aims at obtaining a list of vaccines based on unmet needs in EU, through the following steps :
- Identify all relevant stakeholders in research vaccination: researchers, funders, vaccination networks, industries, health authorities, and participants from civil society from appointed representatives or key opinion leaders, NGOs involved in vaccination to select a representative expert’s group.
- Organize an expert consultation to define one or two vaccines for each pilot age category, for which current coverage in EU MS is suboptimal. This subset of vaccines will constitute a support to propose secondary potential prioritization criteria and develop the priority-setting framework. The pilots will feed into the establishment of an annual list of research priorities on vaccination (D7.2) and will provide input for D7.3.


Sub-Task 7.1.2: Define a concept framework for decision-making on research priorities for the agreed subset of vaccines
Start date: M6 End date: M18
Task description:
Several prioritization methods and tools exist, applied in different contexts and pursuing different objectives. This purpose of this task is to develop and propose a framework adapted to the European context in research, which will be developed through the following steps:
- Establish a list of research prioritization methods and tools from a review of literature and analyze their transferability in an European vaccination research context;
- Choose the most appropriate method;
- Define from literature, and a subset of vaccines identified in sub-task 7.1.1, objective prioritization criteria and method for scoring/rating each criterion;
- Propose a framework for decision-making on research priorities;
- Conduct a web-based consultation of relevant stakeholders to refine the proposed framework.


Sub-Task 7.1.3: Apply framework to define annual EU priorities
Start date: M18 End date: M34
Task description: The framework developed in sub-task 7.1.2 will be applied to define EU
Vaccine hesitancy and uptake. From research and practices to implementation by lead THL

Start month:1 - End month: 36

Co-WP leader: ISS (IT)

Quantitative and qualitative surveys and in depth interviews, targeting Member State representatives, key research and public health community informants, other stakeholders, w...
Co-WP leader: ISS (IT)

Quantitative and qualitative surveys and in depth interviews, targeting Member State representatives, key research and public health community informants, other stakeholders, where appropriate.
Survey of social media data sources. Big data analytic methods. Methods from Network Science. Use of multi-language Big Data sources.
Links with European projects: IMI-ADVANCE, VENICE and the Vaccine confidence project (monitor public confidence in immunization programmes, LSHTM), reminder systems

Task descriptions
Task 8.1: Barriers and enablers behind suboptimal vaccination coverage
Leader: THL Contributors: INSERM, VAZG, MoCA, MoH HDPDP, SSI, HCDCP, ISS, CDPC, SAM, RIVM, FHI, NIPH, IPHS, SK MoH, NIJZ, FMS, FOHM
Collaborating partners: ECDC, WHO, London School of Hygiene and Tropical Medicine (LSHTM).
Start date: M1 End date: M22
Task description This task aims at mapping and creating sustainable mechanisms for reviewing research-based knowledge, including analyses of cultural, social and behavioural determinants (barriers and enablers) behind high or low vaccination coverage and best practices. This review will encompass specific actions and interventions aimed to reduce vaccine hesitancy and increase vaccine uptake, such as tools for HCWs to encounter vaccine hesitant parents, specific campaigns, including health care workers or similar staff; lessons learned in all Member States regardless of their participation in the EU-JAV; among the stakeholders and partners, in the research community, and among policy makers, such as government technical advisors and individuals working with legislation and regulations, including in-depth mapping of knowledge and experiences from existing networks and other projects and programmes, such as VENICE III, Advance, The Vaccine Confidence Project (LSHTM). Added value of surveillance activities will be given specific attention (link with WP5). Results of this task will specifically be linked to WP3 (Evaluation) for assisting with the baseline assessment and to WP5 (Information systems) for improving surveillance and analysis of determinants of lower vaccine coverage.
In this task, survey tools together with qualitative interview methods are applied to determine:
1) what kind of research-based determinants behind high and low vaccination coverage have been identified in the European region including social, cultural and behavioural aspects
2) what kind of practices are known to maintain good vaccination coverage;
3) how have these practices been implemented in the public health work;
4) what lessons have been learned from implementing these practices and what scientific evidence has been produced about the impact of these practices (or interventions).
5) identify cases that can be presented as constructive examples of both successful and unsuccessful actions, practices and decisions.

The following separate work activities will be developed and will feed into activities of task 8.2:
• To map the best practices and lessons learned (from a social, cultural and behavioural point of view) in vaccine hesitancy-related work in the MS and their regions and among stakeholders and partners, research community and existing and ongoing projects and programmes using a web-based survey tool with both close-ended questions and open-ended questions.
• To conduct in-depth interviews complementing the surveys (can be done via skype or similar). A preparatory debrief will be provided to those conducting this task to secure reliability of the results.
• To produce ‘country reports’ on the research-based determinants behind high and low vaccination coverage identified in the region. A template will be provided for the country report, which will be written in English.
• To produce a final report based on the separate country (stakeholder) reports

Task 8.2: Support for effective programme implementation
Leader: THL Contributors: INSERM, VAZG, HCDCP, ISS, SAM, RIVM, FHI, DGS,
Details
Start date: 01/08/2018
End date: 31/03/2022
Duration: 36 month(s)
Current status: Finalised
Programme title: 3rd Health Programme (2014-2020)
EC Contribution: € 3 511 177,02